Recently, Zhejiang Hichi Pharmaceutical Co., Ltd., a subsidiary of Beijing Beilu Pharmaceutical Co., Ltd., received the Iodixanol API product registration certificate issued by the Central Drugs Stand...
Recently, Hichi Pharmaceutical's Iopromide API has received the "Approval Notice for the Marketing Application of Chemical Raw Materials" from the National Medical Products Administratio...
Recently, Beijing Beilu Pharmaceutical Co., Ltd. participated in the centralized volume-based procurement work of pharmaceuticals for the 26-province alliance in the Xinjiang Uygur Autonomous Region. ...
CPHI & PMEC China 2025 recently made a grand debut in Shanghai. This year's exhibition showcases the latest innovations and cutting-edge technologies across the entire pharmaceutical supply ch...
Recently, Beijing Beilu Pharmaceutical Co., Ltd. received the "Marketing Authorization" (MA) for its Iohexol Injection issued by Hungarian National Institute of Pharmacy and Nutrition (OGYÉ...
To facilitate a more in-depth and comprehensive understanding of the Company among a broad base of investors, the Company is scheduled to hold its 2024 Annual Online Performance Presentation on Friday...